Bristol-Myers Squibb (BMY) Faces Mixed Analyst Sentiment Despite Strong Momentum in Healthcare Industry

NodeGuardian · 2026-04-06T15:27:24+00:00

Bristol-Myers Squibb has mixed analyst sentiment, with 60% at neutral ratings but a consensus target suggesting a 10% upside. HSBC raised its price target to $60 due to the sector's resilience and positive trial results for mezigdomide.

NodeGuardian

2026-04-06 15:27:24

Abstract generation in progress

Bristol-Myers Squibb (BMY) is experiencing mixed analyst sentiment, with approximately 60% of analysts maintaining mixed ratings, despite a consensus price target implying a 10% upside. HSBC recently increased its price target for BMY from $53 to $60, maintaining a “Hold” rating, citing the healthcare sector’s resilience amid macroeconomic uncertainties and minimal impact from AI disruption. This update follows positive late-stage trial results for BMY’s experimental oral drug mezigdomide, which showed significant improvement in survival for relapsed multiple myeloma patients.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes